Bristol Myers Squibb is withdrawing the biopharmaceutical giant’s Istodax from the market after recent trials showed that the peripheral T-cell lymphoma drug did not achieve primary efficacy endpoint.
Chemo Drug Potentially More Potent than Remdesivir Against Coronavirus
Antibiotics, Chemotherapeutics, Chemotherapy, China, Clinical Studies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Drug screenings, Peripheral T-Cell Lymphoma (PTCL), PLOS Computational Biology, R&D, Remdesivir, Researchers, RNA, SARS-CoV-2 virus, TherapeuticsThe chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.